Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 5
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
5| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8236962 | VIVJOAoteseconazole | substance, product | Apr 2031 |
| 8754227 | VIVJOAoteseconazole | use | Apr 2031 |
| 11247981 | VIVJOAoteseconazole | use | May 2033 |
| 10414751 | VIVJOAoteseconazole | substance, product | Mar 2036 |
| 9840492 | VIVJOAoteseconazole | substance, product | Mar 2036 |
| Product | Exclusivity | Until |
|---|---|---|
| VIVJOAOTESECONAZOLE | GAIN Qualified infectious disease product (GAIN) | Apr 2032 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| VIVJOA | oteseconazole | capsule, oral | 74695-823NDA |
Enquiry
Common questions
- Is Mycovia Pharmaceuticals, Inc. FDA approved?
- Mycovia Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Mycovia Pharmaceuticals, Inc. make?
- 1 product is listed under Mycovia Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as capsule. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.